



Recombinant Zoster Vaccine: Patient & Provider Essentials

Laura Diamond, MD

10 June 2022

Impact of Herpes Zoster


Increased risk of complications after age 50

- post-herpetic neuralgia
- herpes zoster ophthalmicus (vision loss)
- bacterial superinfection
- cranial and peripheral nerve palsies
- meningoencephalitis



**About 1 in 3 US
adults will
develop Shingles
in their lifetime**



- 
- Review indications, contraindications and special considerations for herpes zoster vaccination
 - Estimate coverage and cost of Recombinant Zoster Vaccine (RZV)
 - Know how to report a possible adverse event using VAERS



Objectives

Case

74 y/o female here today for a Medicare Wellness Visit. Her history is significant for hypertension, CKD stage 3, hyperlipidemia and a liver transplant 9 years ago for chronic HBV and cirrhosis.


Medications: amlodipine 5mg QD, pravastatin 20mg QD, tacrolimus 1mg BID

Is she a candidate for zoster vaccination?

If so, how can you counsel her about the cost of the vaccine?

Indications

- Age > 50
- Age > 18 if (or will be) immunodeficient or immunosuppressed because of disease or therapy





Special Considerations

- Prior shingles
 - No specific time frame
 - Avoid in acute infection
- Prior vaccination with Zostavax
 - Administer Shingrix 5+ years later
 - Earlier is likely fine, base decision on age and risk factors
- Unknown varicella exposure
 - No need to routinely test
 - If varicella serology is available and is negative, follow guidance for varicella immunization



Precautions & Contraindications

- Severe allergic reaction to any component of the vaccine or after initial dose of vaccine
- Current shingles
- Pregnancy

- *Prior Guillain-Barré Syndrome is not a contraindication*



Insurance Coverage

- Medicare
 - Not covered by Parts A and B
 - Part D (*partial or full*)
- Medicaid (*some*)
- Commercial Insurance (*some*)
- Uninsured/Patient Assistance

RZV Cost

\$343.13 series



\$171.57 per dose

GSK *for you*

- No third-party vaccine coverage
- Medicare Part D with having spent over \$600 on prescription medications in the calendar year

<https://www.gskforyou.com/programs/vaccines-patient-assistance/>



Vaccine Adverse Event Reporting

- Vaccine Adverse Event Reporting System (VAERS)
- Anyone can report
- **REQUIRED**
 - Adverse event listed in the [VAERS Table of Reportable Events Following Vaccination](#)
 - Adverse event that is a contraindication to subsequent doses
- **RECOMMENDED**
 - Vaccine administration errors
 - Any adverse event after vaccination, even if causal relationship is uncertain

Vaccine Adverse Event Reporting System (VAERS)

info@VAERS.org
1-800-822-7967



Option 1 - Report Online to VAERS


Submit a VAERS report online. The report must be completed online and submitted in one sitting and cannot be saved and returned to at a later time. Your information will be erased if you are inactive for 20 minutes; you will receive a warning after 15 minutes.



Option 2 - Report using a Writable PDF Form

Download the Writable PDF Form to a computer. Complete the VAERS report offline if you do not have time to complete it all at once. Return to this page to upload the completed Writable PDF form by clicking here.

<https://vaers.hhs.gov/reportevent.html>

- 
- Review indications, contraindications and special considerations for herpes zoster vaccination
 - Estimate coverage and cost of Recombinant Zoster Vaccine (RZV)
 - Know how to report a possible adverse event using VAERS




Summary

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

Weekly / January 28, 2022 / 71(4);109–117

Miwako Kobayashi, MD¹; Jennifer L. Farrar, MPH¹; Ryan Gierke, MPH¹; Amadea Britton, MD^{1,2}; Lana Childs, MPH³; Andrew J. Leidner, PhD¹; Doug Campos-Outcalt, MD⁴; Rebecca L. Morgan, PhD⁵; Sarah S. Long, MD⁶; H. Keipp Talbot, MD⁷; Katherine A. Poehling, MD⁸; Tamara Pilishvili, PhD¹ ([View author affiliations](#))



Resources

- CDC. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP) Recommendations for use of Herpes Zoster Vaccines. *MMWR Recomm Rep*. 2018;67(03):103-108.
- Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. *MMWR Morb Mortal Wkly Rep* 2018;67:103–108. <http://dx.doi.org/10.15585/mmwr.mm6703a5external> icon
- Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. *MMWR*. 2022;71:109–117.
- McGirr A, Widenmaier R, Curran D, Espié E, Mrkvan T, Oostvogels L, Simone B, McElhaney JE, Burnett H, Haeussler K, Thanos A, Wang X, Newson RS. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis. *Vaccine*. 2019 May 16;37(22):2896-2909.

Resources

- Parikh R, Widenmaier R, Lecrenier N. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations. *Expert Rev Vaccines*. 2021 Sep;20(9):1065-1075.
- Singh G, Song S, Choi E, Lee PB, Nahm FS. Recombinant zoster vaccine (Shingrix[®]): a new option for the prevention of herpes zoster and postherpetic neuralgia. *Korean J Pain*. 2020 Jul 1;33(3):201-207.
- Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. *JAMA*. 2011 Jan 12;305(2):160-6.